bioAffinity Technologies Presents CyPath Lung Test at American Cancer Society Roundtable

bioAffinity Technologies' noninvasive CyPath Lung test will be showcased at the American Cancer Society's National Lung Cancer Roundtable. The test successfully identified Stage 1A lung cancer in three patients with atypical and diagnostically challenging presentations. Chief Medical Officer Gordon Downie will present a poster highlighting the cases, demonstrating the test's ability to provide clarity and actionable results in real-world lung nodule practice.